Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice

References

• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015 Apr 13;27(4):450–5. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017 Jan;52:71–81. doi:10.1016/j.ctrv.2016.11.007.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012 Dec;12(12):860–875. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017 Feb;17(2):97–111. doi:10.1038/nri.2016.107.
   PubMed Web of Science ®Google Scholar
• Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki B, De Groote P et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016 Apr 12;15(2):274–287. doi:10.1016/j.celrep.2016.03.037.
   PubMed Web of Science ®Google Scholar
• Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, Hulpiau P, Weber K, Sehon C, Marquis R et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014 May 22;7(4):971–981. doi:10.1016/j.celrep.2014.04.026.
   PubMed Web of Science ®Google Scholar
• Van Hoecke L, Van Lint S, Roose K, Van Parys A, Vandenabeele P, Grooten J, Tavernier J, De Koker S, Saelens X. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nat Commun. 2018 Aug 24;9(1):3417. doi:10.1038/s41467-018-05979-8.
   PubMed Web of Science ®Google Scholar
• Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, et al. Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE). Oncoimmunology. 2019;8(8):1615817. doi:10.1080/2162402X.2019.1615817.
   PubMed Web of Science ®Google Scholar
• Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol. 2014;4:155. doi:10.3389/fonc.2014.00155.
   PubMedGoogle Scholar
• Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019 Sep;18(9):689–706. doi:10.1038/s41573-019-0029-0.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol. 1985 Dec;5(12):3403–3409. doi:10.1128/MCB.5.12.3403.
   PubMed Web of Science ®Google Scholar
• Masternak K, Wittek R. cis- and trans-acting elements involved in reactivation of vaccinia virus early transcription. J Virol. 1996 Dec;70(12):8737–8746. doi:10.1128/JVI.70.12.8737-8746.1996.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Bonilla B, Ashley A, Hou W, Byrd D, Thorne S. Manipulating TLR signaling increases the anti-tumor T cell response induced by viral cancer therapies. Cell Rep. 2016 Apr 12;15(2):264–273. doi:10.1016/j.celrep.2016.03.017.
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847–10851. doi:10.1073/pnas.89.22.10847.
   PubMed Web of Science ®Google Scholar
• Zhu K, Liang W, Ma Z, Xu D, Cao S, Lu X, Liu N, Shan B, Qian L, Yuan J et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis. 2018 May 1;9(5):500. doi:10.1038/s41419-018-0524-y.
   PubMed Web of Science ®Google Scholar
• Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol. 2017 May 19;2(11):eaal1713. doi:10.1126/sciimmunol.aal1713.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015 Apr 30;520(7549):692–696. doi:10.1038/nature14426.
   PubMed Web of Science ®Google Scholar
• Tazawa H, Kuroda S, Hasei J, Kagawa S, Fujiwara T. Impact of autophagy in oncolytic adenoviral therapy for cancer. Int J Mol Sci. 2017 Jul 10;18(7):1479. doi:10.3390/ijms18071479.
   PubMed Web of Science ®Google Scholar
• Ye T, Jiang K, Wei L, Barr MP, Xu Q, Zhang G, Ding C, Meng S, Piao H. Oncolytic newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J Cancer Res. 2018;8:1514–1527.
   PubMed Web of Science ®Google Scholar
• Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, Essand M. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 2020 Jan 22;11(1):48. doi:10.1038/s41419-020-2236-3.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res. 2015 Dec 15;21(24):5543–5551. doi:10.1158/1078-0432.CCR-14-2009.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, Vogt J, Moss B. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol. 2009 Jul;83(14):7176–7184. doi:10.1128/JVI.00687-09.
   PubMed Web of Science ®Google Scholar